Value of Tomita score based on PET/CT to predict survival time in patient with spinal metastases
-
摘要:
目的探讨应用PET-CT检查进行Tomita评分的可行性,验证Tomita评分在脊柱转移瘤患者生存时间预测中的作用。 方法回顾性分析2013年4月~2017年12月我院收治的脊柱转移瘤患者74例,其中男40例、女34例,年龄33~83岁。根据Tomita评分进行分组。A组(2~3分)11例,2例行广泛切除,9例非手术治疗;B组(4~5分)10例,3例行边缘切除,7例非手术治疗;C组(6~7分)15例,3例行姑息手术,12例非手术治疗;D组(8~10分)38例,2例行姑息手术,36例非手术治疗。对4组脊柱转移瘤患者的生存时间进行统计分析。 结果随访2~46月,平均14.7月。患者平均生存时间13.0月:A组23.4月、B组16.3月、C组18.5月、D组7.0月。患者中位生存时间11月:A组21月、B组15月、C组13月、D组6月。Spearman相关性分析结果显示,患者的生存时间与Tomita评分呈负相关,Tomita评分越低,患者生存时间越长,临床预后越好(r= −0.6520,P<0.05)。 结论应用PET-CT进行Tomita评分预测脊柱转移癌患者的生存时间具有可行性,Tomita评分越低,患者生存时间越长,具有方便、准确性高的优点。 Abstract:ObjectiveTo explore the value of Tomita score to predict survival time in patients with spinal metastases. MethodsWe retrospectively collected 74 patients with spinal metastases from April 2013 to December 2017.The patients included 40 male and 34 female, the average age was 57.6 years old. The patients were divided into 4 groups according to Tomita score.Group A: Tomita score 2-3, included 11 patients, 2 operate/9 nonoperate. Group B: Tomita score 4-5, included 10 patients, 2 operate/9 nonoperate. Group C: Tomita score 6-7, included 15 patients, 5 operate/10 nonoperate. Group D: Tomita score 8-10, included 38 patients, 2 operate/36 nonoperate. The survival time and survival rate between the 4 groups were compared. ResultsThe patients were followed up for 2-46 months(14.7 months on avaerage). The average survival time was 13.0 months:23.4 months of Group A, 16.3 months of Group B, 18.5 months of Group C, 7.0 months of Group D. The median survival time was 11 months: 21 months of Group A, 15 months of Group B, 13 months of Group C, 6 months of Group D. The survival time was negatively correlated with Tomita score. Tomita score was lower, while the survival time was longer(r = -0.6520, P<0.05). ConclusionIt is feasibile for PET-CT to grade Tomita score.It can be used easily and accurately to predict the survival time of the patients with spinal metastases. -
Key words:
- spinal metastases /
- Tomita score /
- PET-CT /
- survival time
-
表 1 脊柱肿瘤Tomita评分标准
评分 原发肿瘤 脏器转移情况 脊柱骨转移情况 1分 缓慢生长肿瘤 无 单发或孤立病灶 2分 中速生长肿瘤 有转移,可治 多发病灶 4分 生长迅速或未可知肿瘤 有转移,不可治 - 无脏器转移为0分; “-”为无对应内容; 缓慢生长肿瘤: 乳腺癌, 甲状腺癌, 前列腺癌; 中速生长肿瘤: 肾癌, 子宫内膜癌; 生长迅速肿瘤: 肺癌, 肝癌, 胃癌, 结肠癌. 表 2 各组平均生存时间、中位生存时间情况
组别 例数 中位生存时间(月) 平均生存时间(月) A 11 21 23.4 B 10 15 16.3 C 15 13 18.5 D 38 6 7.0 合计 74 11 13.0 -
[1] Klimo PJ, Schmidt MH. Surgical management of spinal metastases[J]. Oncologist, 2004, 9(2): 188-96. [2] Tomita K, Kawahara N, Kobayashi T, et al. Surgical strategy for spinal metastases[J]. Spine (Phila Pa 1976), 2001, 26(3): 298-306. [3] Ofluoglu O. Minimally invasive manangement of spinal metastases[J]. Orthop Clin North Am, 2009, 40(1): 155-68. [4] 梁堂钊, 万 勇, 龙光华, 等. Tokuhashi外科评分Tokuhashi外科修正评分和Tomita外科评分预测硬膜外脊柱转移瘤患者预后的临床价值[J]. 中华肿瘤杂志, 2010, 32(11): 875-80. doi: 10.3760/cma.j.issn.0253-3766.2010.11.017 [5] 王玉玞, 祖佳宁, 由长城, 等. Tomita及改良Tokuhashi结合脊柱肿瘤不稳评分在脊柱转移瘤可信度和可患者治疗决策中的重复性研究[J]. 中国脊柱脊髓杂志杂志, 2017, 27(9): 805-80. [6] 胡 海, 杨惠林, 王根林, 等. Tomita评分在脊柱转移癌治疗决策与生存时间预测中的作用[J]. 中国脊柱脊髓杂志, 2012, 22(8): 673-7. doi: 10.3969/j.issn.1004-406X.2012.08.01 [7] 曾建成, 宋跃明, 刘 浩, 等. Tomita评分在脊柱转移瘤治疗决策中的意义[J]. 中国脊柱脊髓杂志, 2006, 16(10): 728-31. doi: 10.3969/j.issn.1004-406X.2006.10.002 [8] 锡林宝勒日, 白靖平, 江仁兵, 等. Tomita评分系统在脊柱转移瘤中的应用及评价[J]. 新疆医科大学学报, 2009, 32(12): 1648-50. doi: 10.3969/j.issn.1009-5551.2009.12.003 [9] 孙宇庆, 蔡槱伯, 荣国威. 脊柱转移癌术前评估系统的比较[J]. 中华外科杂志, 2003, 41(8): 13-7. [10] 姜 亮, 刘忠军, 党耕町, 等. 脊柱转移瘤的预后分析[J]. 中国脊柱脊髓杂志, 2005, 15(8): 453-5. doi: 10.3969/j.issn.1004-406X.2005.08.001 [11] 韩 帅, 肖建如. 六种评分系统在脊柱转移瘤患者预后评估应用中的价值[J]. 脊柱外科杂志, 2013, 11(2): 115-7. doi: 10.3969/j.issn.1672-2957.2013.02.013 [12] 毛庆聪, 徐文贵, 戴 东. 18F-FDG PET/CT显像对脊柱单发肿瘤的诊断价值[J]. 中华核医学与分子影像杂志, 2013, 33(3): 179-83. doi: 10.3760/cma.j.issn.2095-2848.2013.03.006 [13] 尹莉萍, 李文斌, 付 政. PET/CT与MRI对脊柱转移瘤的检出比较[J]. 重庆医学, 2011, 40(1): 82-3. doi: 10.3969/j.issn.1671-8348.2011.01.039 [14] 李欣欣, 张志山, 张燕燕, 等. PET/CT显像用于脊柱转移瘤Tomita评分[J]. 中华核医学与分子影像杂志, 2017, 37(2): 31-4. [15] 李鹏飞, 刘剑锋. 微波消融结合椎板减压内固定术治疗脊柱转移瘤[J]. 实用骨科杂志, 2018, 24(2): 159-62. [16] Tokuhashi Y, Ajiro Y, Umezawa N. Outcome of treatment for spinal metastases using scoring system for preoperative evaluation of prognosis[J]. Spine (Phila Pa 1976), 2009, 34(1): 69-73. [17] Bauer HC, Wedin R. Survival after surgery for spinal and extremity metastases. Prognostication in 241 patients[J]. Acta Orthop Scand, 1995, 66(2): 143-6. [18] Uchida K, Nakajima H, Miyazaki T, et al. 18F-FDG PET/CT for diagnosis of osteosclerotic and osteolytic vertebral metastatic lesions:comparision with bone scintigraphy[J]. Asian Spine J, 2013, 7(2): 96-103. [19] 郭本树, 熊延新, 林曰增, 等. 脊柱转移瘤MR扫描与核素骨显像的对比研究[J]. 实用放射学杂志, 2006, 9(9): 1097-100. doi: 10.3969/j.issn.1002-1671.2006.09.021 [20] 高智颖, 肖建如. PET/CT在脊柱肿瘤外科的应用[J]. 国际骨科学杂志, 2010, 31(2): 71-2, 94. doi: 10.3969/j.issn.1673-7083.2010.02.003 [21] 朱亚莉, 陈东方, 龚向阳, 等. MRI与18F-FDG PET/CT对脊柱转移瘤病变检出的一致性研究[J]. 实用放射学杂志, 2017, 33(7): 1073-6. doi: 10.3969/j.issn.1002-1671.2017.07.023 [22] Tatusi H, 0nomura T, Morishita S, et al. Survival rates of patients with metastatic spinal cancer after scintigraphic detection of abnormal radioactive accumu lation[J]. Spine (Phila Pa 1976), 1996, 2(18): 2143-8. [23] Finkelstein JA, Zaveri C, Wai E, et al. A population-based study of sugery for spinal metastases[J]. J Bone Joint Surg, 2003, 85(7): 1045-50.
计量
- 文章访问数: 1536
- HTML全文浏览量: 688
- PDF下载量: 7
- 被引次数: 0